CASP1 and myocardial ischemia: Collectively, the application of novel targeted inhibition of the NLRP3/caspase 1/GSDMD axis holds significant promise as a therapeutic strategy for mitigating myocardial injury and inflammation in IHD, as evidenced by the robust protective effects observed in both in vitro and in vivo models.